OncoMed Absorbs Double Dose Of Bad News With Trial Failure, Two Options Declined
The California biotech's Phase II pancreatic cancer candidate demcizumab failed to show benefit versus placebo for progression-free or overall survival. Meanwhile, Bayer decided not to exercise its options on a pair of Wnt pathway candidates under a 2010 collaboration with OncoMed.
You may also be interested in...
Halozyme’s Spotlight Shifts To Enhanze Exclusively After PEGPH20 Fails In Phase III
The Enhanze drug delivery technology, which is expected to be profitable starting next year, takes center stage as Halozyme discontinues PEGPH20 development and cuts its oncology operations along with 160 jobs.
Deal Watch: Takeda Teams With Molecular Templates On Anti-CD38 Approach To Multiple Myeloma
Takeda and Molecular Templates will work to develop targeted engineered toxin bodies for multiple myeloma. Celgene decides against optioning OncoMed’s navicixizumab for ovarian cancer, while CRISPR and ViaCyte team up on type 1 diabetes.
Finance Watch: $50m Doubles Magenta's Funding To Improve Stem Cell Transplants
In VC deals, Magenta raised $50m, licensed a Novartis asset and engaged an important partner. Seven public companies revealed financial transactions totaling $947.4m, including Achaogen's $20.5m from the Gates Foundation. Also, OncoMed, Regulus and Depomed provided restructuring updates.